

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined in this announcement, terms defined in the prospectus dated 28 October 2014 (the “**Prospectus**”) issued by Austar Lifesciences Limited (the “**Company**”) have the same meanings when used in this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. The information contained in this announcement is not for distribution, directly or indirectly, in or into the United States. This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. Securities may not be offered or sold in the United States unless they are registered under applicable laws or are exempt from registration under the US Securities Act, as amended. No public offer of securities of the Company will be made in the United States. This announcement is made pursuant to the requirement under section 9(2) of the Securities and Futures (Price Stabilizing) Rules.



# AUSTAR

## Austar Lifesciences Limited

### 奧星生命科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6118)

## **PARTIAL EXERCISE OF OVER-ALLOTMENT OPTION, STABILIZATION ACTIONS AND END OF STABILIZATION PERIOD**

### **PARTIAL EXERCISE OF OVER-ALLOTMENT OPTION**

The Company announces that the Over-allotment Option was exercised partially by the Sole Global Coordinator, on behalf of the International Underwriters, on 28 November 2014 in respect of an aggregate of 12,582,000 Shares (the “**Over-allotment Shares**”), representing approximately 10.07% of the total number of Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option, to facilitate the return of part of the 18,750,000 Shares borrowed by the Stabilizing Manager from SFH under the Stock Borrowing Agreement, which were used to cover over-allocations in the International Placing. The Over-allotment Shares will be allotted and issued by the Company at HK\$3.12 per Share excluding brokerage of 1%, Stock Exchange trading fee of 0.005% and SFC transaction levy of 0.0027%, being the Offer Price under the Global Offering and are expected to be allotted and issued on 3 December 2014.

## **STABILIZATION ACTIONS AND END OF STABILIZATION PERIOD**

The Company further announces that the stabilization period in connection with the Global Offering ended on 28 November 2014, being the last business day immediately before the 30th day after the last day for the lodging of applications under the Hong Kong Public Offer. The stabilization actions that have been taken by the Stabilizing Manager during the stabilization period were:

- (1) over-allocations of an aggregate of 18,750,000 Shares in the International Placing, representing 15% of the total number of Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option;
- (2) the borrowing of an aggregate of 18,750,000 Shares from SFH pursuant to the Stock Borrowing Agreement to facilitate the delivery of securities in connection with the over-allocations in the International Placing;
- (3) the purchase of an aggregate of 8,151,000 Shares at the price ranging from HK\$2.98 to HK\$3.12 per Share on the market (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Hong Kong Stock Exchange trading fee of 0.005%) during the stabilization period;
- (4) the sale of an aggregate of 1,983,000 Shares acquired by the Stabilizing Manager or its agent in the course of the primary stabilizing action in order to liquidate positions that were established by such action at the price ranging from HK\$3.16 to HK\$3.32 per Share; and
- (5) partial exercise of the Over-allotment Option by the Sole Global Coordinator on 28 November 2014 in respect of 12,582,000 Shares, representing approximately 10.07% of the total number of Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option, at the Offer Price to facilitate the return of part of the 18,750,000 Shares borrowed by the Stabilizing Manager from SFH under the Stock Borrowing Agreement, which were used to cover the over-allocations in the International Placing.

The last purchase made by the Stabilizing Manager or its agent on the market during the course of the stabilizing period was on 28 November 2014 at the price of HK\$3.11 per Share (excluding brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%).

This announcement is made pursuant to Section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong).

## **PARTIAL EXERCISE OF OVER-ALLOTMENT OPTION**

The Company announces that the Over-allotment Option was exercised partially by the Sole Global Coordinator, on behalf of the International Underwriters, on 28 November 2014 in respect of an aggregate of 12,582,000 Shares, representing approximately 10.07% of the total number of Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option, to cover over-allocations in the International Placing.

The Over-allotment Shares will be allotted and issued by the Company at HK\$3.12 per Share excluding brokerage of 1%, Stock Exchange trading fee of 0.005% and SFC transaction levy of 0.0027%, being the Offer Price under the Global Offering. The Over-allotment Shares are expected to be allotted and issued on 3 December 2014.

The Over-allotment Shares will be used to facilitate the return of part of the 18,750,000 Shares borrowed by the Stabilizing Manager from SFH under the Stock Borrowing Agreement, which were used to cover over-allocations in the International Placing. Immediately after the allotment and issue by the Company of the Over-allotment Shares, approximately 26.84% of the issued share capital of the Company will be held by the public in compliance with Rule 8.08 of the Listing Rules.

Approval for the listing of and permission to deal in the Over-allotment Shares has already been granted by the Listing Committee of the Stock Exchange. Listing of and dealing in such Over-Allotment Shares are expected to commence on the Main Board of the Hong Kong Stock Exchange at 9:00 a.m. on 4 December 2014.

The shareholding structure of the Company immediately before and immediately after the completion of the allotment and issue of the Over-allotment Shares is as follows:

Shareholder	Immediately before the allotment and issue of the Over-allotment Shares		Immediately after the allotment and issue of Over-allotment Shares	
	Number of Shares	Approximate percentage of the Company's issued share capital	Number of Shares	Approximate percentage of the Company's issued share capital
SFH ( <i>Notes 1 and 4</i> )	333,750,000	66.75%	333,750,000	65.11%
HCV ( <i>Notes 2 and 4</i> )	3,750,000	0.75%	3,750,000	0.73%
TWG ( <i>Notes 3 and 4</i> )	37,500,000	7.50%	37,500,000	7.32%
Public	<u>125,000,000</u>	<u>25.00%</u>	<u>137,582,000</u>	<u>26.84%</u>
Total	<u><u>500,000,000</u></u>	<u><u>100.00%</u></u>	<u><u>512,582,000</u></u>	<u><u>100.00%</u></u>

*Notes:*

- (1) These Shares are registered in the name of SFH, a company wholly-owned by Mr. Mars Ho, the Chairman and an executive Director.
- (2) These Shares are registered in the name of HCV, a company wholly-owned by Madam Gu, who is the spouse of Mr. Mars Ho.
- (3) These Shares are registered in the name of TWG, a company wholly-owned by Mr. KH Ho, an executive Director.
- (4) The Shares held by SFH, HCV and TWG are not considered as held by public for the purpose of the Listing Rules.

The additional net proceeds of approximately HK\$38.1 million, after deducting the underwriting fees and commissions, from the issue of the Over-allotment Shares by the Company will be used for the purposes as set out in the section headed "Future Plans and Use of Proceeds – Proposed Use of Proceeds" in the Prospectus.

## STABILIZATION ACTIONS AND END OF STABILIZATION PERIOD

The Company further announces that the stabilization period in connection with the Global Offering ended on 28 November 2014, being the last business day immediately before the 30th day after the last day for lodging applications under the Hong Kong Public Offer.

The stabilization actions that have been taken by the Stabilization Manager during the stabilization period were:

- (1) over-allocations of an aggregate of 18,750,000 Shares in the International Placing, representing 15% of the total number of Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option;
- (2) the borrowing of an aggregate of 18,750,000 Shares from SFH pursuant to the Stock Borrowing Agreement to facilitate the delivery of securities in connection with the over-allocations in the International Placing;
- (3) the purchase of an aggregate of 8,151,000 Shares at the price ranging from HK\$2.98 to HK\$3.12 per Share on the market (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Hong Kong Stock Exchange trading fee of 0.005%) during the stabilization period;
- (4) the sale of an aggregate of 1,983,000 Shares acquired by the Stabilizing Manager or its agent in the course of the primary stabilising action in order to liquidate positions that were established by such action at the price ranging from HK\$3.16 to HK\$3.32 per Share; and
- (5) partial exercise of the Over-allotment Option by the Sole Global Coordinator on 28 November 2014 in respect of 12,582,000 Shares, representing approximately 10.07% of the total number of Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option, at the Offer Price to facilitate the return of part of the 18,750,000 Shares borrowed by the Stabilizing Manager from SFH under the Stock Borrowing Agreement, which were used to cover over-allocations in the International Placing.

The last purchase made by the Stabilizing Manager or its agent on the market during the course of the stabilising period was on 28 November 2014 at the price of HK\$3.11 per Share (excluding brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%).

The Company continues to comply with the public float requirements under Rule 8.08(1)(d) of the Listing Rules. No new shares or securities convertible into equity securities of the Company may be issued within six months from the Listing Date save for the situations set out in Rule 10.08 of the Listing Rules.

By order of the Board  
**Austar Lifesciences Limited**  
**Ho Kwok Keung, Mars**  
*Chairman and Chief Executive Officer*

Hong Kong, 28 November 2014

*As of the date of this announcement, the executive Directors are Mr. Ho Kwok Keung, Mars, Mr. Ho Kin Hung, Mr. Chen Yuewu and Madam Zhou Ning; the non-executive Directors are Mr. Enzo Barazetti and Madam Ji Lingling; and the independent non-executive Directors are Mr. Cheung Lap Kei, Madam Chiu Hoi Shan and Mr. Raco Ivan Jordanov (alias Racho Jordanov).*

*This announcement is available for viewing on the website of the Company at [www.austar.com.hk](http://www.austar.com.hk) and the website of the Hong Kong Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk).*